CADENCE PHARMACEUTICALS INC 4
4 · CADENCE PHARMACEUTICALS INC · Filed Jun 11, 2013
Insider Transaction Report
Form 4
Byrd Scott A.
SVP, Chief Commercial Officer
Transactions
- Sale
common stock
2013-06-07$7.53/sh−67,115$505,201→ 2,000 total - Exercise/Conversion
common stock
2013-06-07$3.51/sh+30,657$107,606→ 32,657 total - Exercise/Conversion
stock option (right to buy)
2013-06-07−36,458→ 88,542 totalExercise: $3.51Exp: 2022-03-14→ common stock (36,458 underlying) - Exercise/Conversion
common stock
2013-06-07$3.51/sh+36,458$127,968→ 69,115 total - Exercise/Conversion
stock option (right to buy)
2013-06-07−30,657→ 0 totalExercise: $3.51From: 2012-09-14Exp: 2022-03-14→ common stock (30,657 underlying)
Footnotes (4)
- [F1]The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2013.
- [F2]This transaction was executed in multiple trades at prices ranging from a low of $7.39 to a high of $7.79. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]Not applicable to this transaction.
- [F4]31,250 of the options vested and became exercisable on March 14, 2013; and 2,604 of the options vested and became exercisable on each of April 1, 2013 and May 1, 2013.